about
Impact of rhinitis on airway inflammation: biological and therapeutic implicationsPatient engagement and patient support programs in allergy immunotherapy: a call to action for improving long-term adherenceManagement of the polyallergic patient with allergy immunotherapy: a practice-based approachRecommendations for appropriate sublingual immunotherapy clinical trialsThe WEB-based Asthma Control: an intriguing connection or a dangerous hazard?Single-dose oral tolerance test with alternative compounds for the management of adverse reactions to drugsEvaluation of food-pollen cross-reactivity by nose-mouth cross-challenge in pollinosis with oral allergy syndromeLocal allergic rhinitis: entopy or spontaneous response?Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization StatementEAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy.Sublingual immunotherapy: World Allergy Organization position paper 2013 update.Diagnostic tools in Rhinology EAACI position paperARIA update: I--Systematic review of complementary and alternative medicine for rhinitis and asthma.Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials.Possible role of climate changes in variations in pollen seasons and allergic sensitizations during 27 years.Lack of neo-sensitization to Pen a 1 in patients treated with mite sublingual immunotherapy.Nasal cytology: the "infectious spot", an expression of a morphological-chromatic biofilm.Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009.Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System.Effects of different up-dosing regimens for hymenoptera venom immunotherapy on serum CTLA-4 and IL-10.COPD: maximization of bronchodilation.A survey of clinical features of allergic rhinitis in adults.Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials.Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen).Allergic rhinitis and its impact on asthma update: allergen immunotherapy.Role of leukotriene receptor antagonists in the management of mild-to-moderate asthma.Allergic and non-allergic rhinitis in swimmers: clinical and cytological aspects.When sneezing indicates the cell type.Allergic and non-allergic rhinitis: relationship with nasal polyposis, asthma and family history.Structure and classification of H1-antihistamines and overview of their activities.The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis.The care pathway for children with urticaria, angioedema, mastocytosisNoninjection routes for immunotherapy.Oral and sublingual immunotherapy in paediatric patients.Vitamin D, allergies and asthma: focus on pediatric patients.Allergen biodistribution in humans.Safety of allergen-specific sublingual immunotherapy and nasal immunotherapy.Effects of fexofenadine and other antihistamines on components of the allergic response: adhesion molecules.Focus on cat allergen (Fel d 1): immunological and aerodynamic characteristics, modality of airway sensitization and avoidance strategies.
P50
Q24798667-66272A6D-1547-46A2-9452-124E9DF33728Q26740381-B0B8C9D9-FE56-4992-B682-212CE577E9ECQ26772200-297595EB-0E8B-4031-88B7-40607EABF6AFQ27011713-03D96EA9-9D27-43C2-87BA-AC63C61DA3FDQ28078728-EA77DA6D-7BD2-4594-8EA4-7295594DDC74Q28194265-1272AB85-55B4-4D01-AE0D-EF6E7ED147E0Q28236487-F86774E2-EA6A-4485-B35E-8795339154DFQ30368010-70A240A1-A6F8-4510-BE8E-60CA94CCD158Q30371972-A97CB4A7-1BCA-481F-B29D-39DC80D3F936Q30394524-E672CF2A-1C92-43AC-88EA-C0CA16ACA4EDQ30440195-6872F03D-9729-45FB-B958-96B09FD23B76Q30469747-F235C2B6-EF11-4AF7-88D9-8D4E42A901EBQ33242321-4C7BF7F9-DC67-4749-93E3-0214E0F43DEFQ33362544-F8111BE9-8A16-4170-8CB5-AF4CB112D33FQ33550915-40A11C1A-9B01-4812-B1EB-9E6AA141E17CQ33810733-2D7A96D9-EE3A-4BF9-9EAB-C2732283686EQ33832286-7D13E647-C450-45AE-BA62-3AC121E05557Q34090431-367FF97F-FFB9-49F0-993B-B97EB1A3A532Q34097796-AD10B943-5B91-47B3-A785-2830D32E533DQ34313790-58AC7F17-008C-4A13-9888-D61D66EDCE63Q34436393-437505DD-9315-435F-BCD3-65FA18B54CD6Q34496568-2E9E00CA-273B-42E9-8F86-6BBA613176E4Q34544937-7F3F4E4A-7985-4B0D-8675-A1EF4935D830Q34561153-F90EFBBD-9314-435A-85F5-205FF0DF58BAQ34589248-455EE248-95D7-4014-B027-592983D8E894Q34617277-CBCEA1DA-9DFE-4141-ADC4-A376B99850CCQ34617299-1D69C0A4-5E10-41C2-81CD-C16DA0F5C451Q34621017-63274BE1-24EF-48F2-A521-B6FBD65F2D5FQ34645810-1ECCB94F-4194-40D2-A7BB-5CDD7FF0559AQ34661107-DB5F8350-0352-439E-A2BC-CAD0C8D44BD5Q34734498-B3F95EA5-3D0A-4200-AD71-846D8089390DQ35005943-96DA21FB-09B6-4B2E-B9E5-40B6F8D4A15DQ35036770-825AD466-81A7-4D26-BDF1-049A0B298746Q35087289-6E99D120-6F99-478A-A539-4C794B6DDA46Q35128859-5E1A0B0B-BAAE-4ED0-A1FF-1591B6CE4180Q35187318-228463E0-C912-40A6-9523-E2670F42C690Q35208951-04F455E8-3B7B-49B7-ABD6-7A21A2D608B5Q35208960-FA5AB6C5-370C-454D-98E6-D6E96208148BQ35552828-39DB67B8-5129-410E-9F2B-FBF3DE06BA7AQ35557993-3C67CD7C-AB66-45AD-915D-A8C2C80E4A0F
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
հետազոտող
@hy
研究者
@zh
name
Giovanni Passalacqua
@ast
Giovanni Passalacqua
@en
Giovanni Passalacqua
@es
Giovanni Passalacqua
@nl
type
label
Giovanni Passalacqua
@ast
Giovanni Passalacqua
@en
Giovanni Passalacqua
@es
Giovanni Passalacqua
@nl
prefLabel
Giovanni Passalacqua
@ast
Giovanni Passalacqua
@en
Giovanni Passalacqua
@es
Giovanni Passalacqua
@nl
P21
P31
P496
0000-0002-5139-3604